NCT05529901Active, not recruiting
Japan Post Marketing Surveillance of the GORE® CARDIOFORM Septal Occluder
Post Marketing Surveillance of the GORE® CARDIOFORM Septal Occluder
Source: ClinicalTrials.gov · Last updated 20 Nov 2025
Brief summary (registry, in English)
The purpose of this post-marketing surveillance is to evaluate the effectiveness and safety of GORE® CARDIOFORM Septal Occluder under the post-marketing setting in Japan.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 23 Aug 2022
- Start date
- 3 Oct 2022
- Primary completion date
- Aug 2029
- Lead sponsor
- W.L.Gore & Associates
- Diseases
- Stroke
- NCT number
- NCT05529901
What you commit to
- Study type: Observational
- Planned participants: 300
- From 3 Oct 2022 to the primary completion date, Aug 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- N/A
Who the study is looking for
- Diagnosed with cryptogenic stroke (including transient ischemic attack with positive head imaging findings)
- Diagnosed with a PFO
- Note: Additional Inclusion Criteria may apply
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Okayama University Hospital Coordinator of this site? Confirm its status | Okayama | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.